Q32 Bio (QTTB) Capital Expenditures Growth (1y) (2018 - 2025)
Q32 Bio (QTTB) Capital Expenditures Growth (1y) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Q32 Bio | 215.94 Mn | 165.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 324.02% |
| Sep 30, 2025 | -205.96% |
| Jun 30, 2025 | 278.00% |
| Mar 31, 2025 | 185.22% |
| Sep 30, 2024 | 58,600.00% |
| Jun 30, 2024 | -470.37% |
| Mar 31, 2024 | 600.00% |
| Sep 30, 2023 | -83.33% |
| Jun 30, 2023 | -97.77% |
| Mar 31, 2023 | -138.98% |
| Dec 31, 2022 | -99.62% |
| Sep 30, 2022 | 100.39% |
| Jun 30, 2022 | -0.25% |
| Mar 31, 2022 | -83.92% |
| Dec 31, 2021 | 516.58% |
| Sep 30, 2021 | -339.10% |
| Jun 30, 2021 | 160.61% |
| Mar 31, 2021 | -81.95% |
| Dec 31, 2020 | -102.68% |
| Sep 30, 2020 | 104.12% |